Dynavax Technologies (DVAX) 8-K Dynavax Reports Interim, One-Year Data from Ragweed Allergy Trial at AAAAI

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):February 23, 2007

DYNAVAX TECHNOLOGIES
CORPORATION

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of
incorporation) 000-50577
(Commission File Number) 33-0728374
(I.R.S. Employer Identification
No.)

2929 Seventh Street, Suite 100
Berkeley, California 94710
(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (510) 848-5100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.    Other Events.

     In a press release dated February 23, 2007, Dynavax Technologies Corporation announced one-year data from the DARTT ragweed allergy trial and the decision to discontinue both the DARTT and pediatric TOLAMBA trials.

     The press release dated February 23, 2007, titled “Dynavax Reports Interim, One-Year Data from Ragweed Allergy Trial at AAAAI” is attached hereto as Exhibit 99.1 and is herein incorporated by reference.

Item 9.01.   Financial Statements and Exhibits.

     (d) Exhibits.

Exhibit No.	Description
99.1	Press release, dated February 23, 2007, entitled “Dynavax Reports Interim, One-Year Data from Ragweed Allergy Trial at AAAAI.”

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Dynavax Technologies Corporation
Dated: February 27, 2007	By:	/s/ Deborah A. Smeltzer
		Deborah A. Smeltzer, Vice President,
		Operations and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit
Number	Description
99.1	Press release, dated February 23, 2007, entitled “Dynavax Reports Interim, One-Year Data from Ragweed Allergy Trial at AAAAI.”